NRx Pharmaceuticals Subsidiary to Acquire Stake in Florida Neuropsychiatry Clinic

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) announced its subsidiary HOPE Therapeutics, Inc. has signed a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a neuropsychiatry clinic in Florida. This acquisition is anticipated to be immediately accretive to revenue and EBITDA, marking a significant step in HOPE Therapeutics' expansion strategy towards operating 30 clinics with a $100 million run rate by the end of 2025. Cohen and Associates, located in the Sarasota-Bradenton area, specializes in treatments for mood disorders, PTSD, and suicidal depression, including ketamine infusions and transcranial magnetic stimulation (TMS). The clinic, led by Dr. Rebecca Cohen, will serve as a foundational location for HOPE's growing network. For more details on the acquisition, visit https://ibn.fm/geIxF.